Unicycive(UNCY) - 2024 Q4 - Annual Results

Exhibit 99.1 Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial Planning in Preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, California, March 31, 2025 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology co ...